支持开放科学:临床与实验医学进展》和预印本。

IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Advances in Clinical and Experimental Medicine Pub Date : 2024-10-01 DOI:10.17219/acem/193956
Marek Misiak, Donata Kurpas
{"title":"支持开放科学:临床与实验医学进展》和预印本。","authors":"Marek Misiak, Donata Kurpas","doi":"10.17219/acem/193956","DOIUrl":null,"url":null,"abstract":"<p><p>This editorial outlines the issue of preprints in scholarly communication. It presents the policy regarding them in Advances in Clinical and Medical Problems and a summary of papers released as preprints and subsequently published in this journal or rejected until July 10, 2024. The introduction discusses the definition of preprint, and leading preprint servers are listed. Policies of 2 such services - Research Square and medRxiv - most frequently chosen by Adv Clin Exp Med authors are then described, followed by a broad outline of the advantages of preprints and controversies surrounding them, based on selected literature on this topic. The next section discusses the policies of most renowned medical journals and publishers regarding preprints. The preprint policy of Adv Clin Exp Med is then thoroughly explained, as well as its reasons. All papers previously released as preprints and published in this journal in 2021-2024 are presented, focusing on meaningful differences between them. Rejected papers previously released as preprints, submitted to Adv Clin Exp Med in 2022-2024, are also listed and discussed. The conclusion is that the basis for endorsing preprints in this journal is not that they benefit this journal but that they serve the scientific community as a whole and science in general by facilitating rapid dissemination of results and fostering immediate assessment of those results by other investigators and debate around them. The most justified line of action is educating authors about the benefits and problems related to preprints.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1045-1068"},"PeriodicalIF":2.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Supporting open science: Advances in Clinical and Experimental Medicine and preprints.\",\"authors\":\"Marek Misiak, Donata Kurpas\",\"doi\":\"10.17219/acem/193956\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This editorial outlines the issue of preprints in scholarly communication. It presents the policy regarding them in Advances in Clinical and Medical Problems and a summary of papers released as preprints and subsequently published in this journal or rejected until July 10, 2024. The introduction discusses the definition of preprint, and leading preprint servers are listed. Policies of 2 such services - Research Square and medRxiv - most frequently chosen by Adv Clin Exp Med authors are then described, followed by a broad outline of the advantages of preprints and controversies surrounding them, based on selected literature on this topic. The next section discusses the policies of most renowned medical journals and publishers regarding preprints. The preprint policy of Adv Clin Exp Med is then thoroughly explained, as well as its reasons. All papers previously released as preprints and published in this journal in 2021-2024 are presented, focusing on meaningful differences between them. Rejected papers previously released as preprints, submitted to Adv Clin Exp Med in 2022-2024, are also listed and discussed. The conclusion is that the basis for endorsing preprints in this journal is not that they benefit this journal but that they serve the scientific community as a whole and science in general by facilitating rapid dissemination of results and fostering immediate assessment of those results by other investigators and debate around them. The most justified line of action is educating authors about the benefits and problems related to preprints.</p>\",\"PeriodicalId\":7306,\"journal\":{\"name\":\"Advances in Clinical and Experimental Medicine\",\"volume\":\" \",\"pages\":\"1045-1068\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Clinical and Experimental Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.17219/acem/193956\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17219/acem/193956","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

这篇社论概述了学术交流中的预印本问题。它介绍了《临床与医学问题进展》中有关预印本的政策,以及在2024年7月10日之前作为预印本发布并随后在该期刊上发表或被拒的论文摘要。引言讨论了预印本的定义,并列出了主要的预印本服务器。然后介绍了 Adv Clin Exp Med 作者最常选择的 2 个此类服务--Research Square 和 medRxiv--的政策,随后根据有关该主题的部分文献,概括介绍了预印本的优势以及围绕预印本的争议。下一部分将讨论大多数知名医学期刊和出版商的预印本政策。随后,将详细解释《临床前医学》的预印本政策及其原因。本节介绍了 2021-2024 年期间以预印论文形式发布并发表在本期刊上的所有论文,并重点介绍了这些论文之间的差异。此外,还列出并讨论了 2022-2024 年投给《Adv Clin Exp Med》的被拒论文。结论是,支持在本刊发表预印本的依据并不是预印本有利于本刊,而是预印本有利于整个科学界和整个科学,因为预印本可以促进成果的快速传播,促进其他研究者对这些成果进行即时评估,并围绕这些成果展开讨论。最合理的做法是让作者了解预印本的好处和问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Supporting open science: Advances in Clinical and Experimental Medicine and preprints.

This editorial outlines the issue of preprints in scholarly communication. It presents the policy regarding them in Advances in Clinical and Medical Problems and a summary of papers released as preprints and subsequently published in this journal or rejected until July 10, 2024. The introduction discusses the definition of preprint, and leading preprint servers are listed. Policies of 2 such services - Research Square and medRxiv - most frequently chosen by Adv Clin Exp Med authors are then described, followed by a broad outline of the advantages of preprints and controversies surrounding them, based on selected literature on this topic. The next section discusses the policies of most renowned medical journals and publishers regarding preprints. The preprint policy of Adv Clin Exp Med is then thoroughly explained, as well as its reasons. All papers previously released as preprints and published in this journal in 2021-2024 are presented, focusing on meaningful differences between them. Rejected papers previously released as preprints, submitted to Adv Clin Exp Med in 2022-2024, are also listed and discussed. The conclusion is that the basis for endorsing preprints in this journal is not that they benefit this journal but that they serve the scientific community as a whole and science in general by facilitating rapid dissemination of results and fostering immediate assessment of those results by other investigators and debate around them. The most justified line of action is educating authors about the benefits and problems related to preprints.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in Clinical and Experimental Medicine
Advances in Clinical and Experimental Medicine MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
3.70
自引率
4.80%
发文量
153
审稿时长
6-12 weeks
期刊介绍: Advances in Clinical and Experimental Medicine has been published by the Wroclaw Medical University since 1992. Establishing the medical journal was the idea of Prof. Bogumił Halawa, Chair of the Department of Cardiology, and was fully supported by the Rector of Wroclaw Medical University, Prof. Zbigniew Knapik. Prof. Halawa was also the first editor-in-chief, between 1992-1997. The journal, then entitled "Postępy Medycyny Klinicznej i Doświadczalnej", appeared quarterly. Prof. Leszek Paradowski was editor-in-chief from 1997-1999. In 1998 he initiated alterations in the profile and cover design of the journal which were accepted by the Editorial Board. The title was changed to Advances in Clinical and Experimental Medicine. Articles in English were welcomed. A number of outstanding representatives of medical science from Poland and abroad were invited to participate in the newly established International Editorial Staff. Prof. Antonina Harłozińska-Szmyrka was editor-in-chief in years 2000-2005, in years 2006-2007 once again prof. Leszek Paradowski and prof. Maria Podolak-Dawidziak was editor-in-chief in years 2008-2016. Since 2017 the editor-in chief is prof. Maciej Bagłaj. Since July 2005, original papers have been published only in English. Case reports are no longer accepted. The manuscripts are reviewed by two independent reviewers and a statistical reviewer, and English texts are proofread by a native speaker. The journal has been indexed in several databases: Scopus, Ulrich’sTM International Periodicals Directory, Index Copernicus and since 2007 in Thomson Reuters databases: Science Citation Index Expanded i Journal Citation Reports/Science Edition. In 2010 the journal obtained Impact Factor which is now 1.179 pts. Articles published in the journal are worth 15 points among Polish journals according to the Polish Committee for Scientific Research and 169.43 points according to the Index Copernicus. Since November 7, 2012, Advances in Clinical and Experimental Medicine has been indexed and included in National Library of Medicine’s MEDLINE database. English abstracts printed in the journal are included and searchable using PubMed http://www.ncbi.nlm.nih.gov/pubmed.
期刊最新文献
Development and validation of the antibody-dependent cellular phagocytosis-based signature: A prognostic risk model of gastric cancer. Laboratory synthesis and preparation of thermo-responsive polymeric micelle and hydrogel for resveratrol delivery and release. Otolaryngological manifestations in patients with obstructive sleep apnea and continuous positive airway pressure users: A systematic review. Prognostic value of inflammation-related model in hepatitis B acute-on-chronic liver failure. Research status and controversy on non-small cell lung cancer stem cells.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1